2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.
Thomas G. Martin, MD, director of clinical research, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses recent key advances in multiple myeloma.
The field of myeloma is moving toward optimizing frontline therapy for patients with transplant-eligible and -ineligible disease, Martin says. Moreover, a greater understanding of how to best treat patients who relapse early is emerging. Additionally, several therapies have been approved for use in patients with triple-class refractory multiple myeloma, which hadpreviously been an unmet need, Martin explains
Research efforts are evaluating many novel treatments, including bispecific T-cell engagers, Martin continues. Moreover, these therapeutics are eliciting responses in patients with heavily pretreated disease, Martin concludes.